Curbing Prescription Drug Abuse in Medicaid

Similar documents
Idaho DUR Board Meeting Minutes

Managed Care Pushes for Safer Opioid Oversight

Unintentional Poisonings: Public Health Response Joint Legislative Health Care Oversight Committee

2018 Annual Meeting & Educational Conference Opioids In Workers Compensation: Research From WCRI

Idaho DUR Board Meeting Minutes

Medicaid and the Opioid Crisis

A nation in pain: Focus on Medicaid

MEDICAL ASSISTANCE BULLETIN

North Carolina, like the rest of the nation, has been experiencing

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

TennCare Joint Committee for the Review of Narcotic Management Meeting Minutes

The Opioid Epidemic: The State of the State

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

Michigan Legislative and Regulatory Pharmacy Initiatives Update

NBPDP Drug Utilization Review Process Update

Although PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.

Tracker e-prescribing 101. The Complete Guide

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

General Providers. Tamper-Resistant Prescription Requirements

Idaho DUR Board Meeting Minutes

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

7/17/2017. FSHP 2017 ANNUAL MEETING Nothing to disclose. Opioid Overuse: National Epidemic. Opioid Epidemic: CDC Data

WA PMP Access by Public Payers. PDMP North Regional Meeting St. Louis, MO April 23-24

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Opiate Use among Ohio Medicaid Recipients

See Important Reminder at the end of this policy for important regulatory and legal information.

Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices

Patient Review and Coordination Program

Proposed Revision to Med (i)

What is the strategy?

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

Medicaid Perspective

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

D. Todd Bess, PharmD 1

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

literature that drug combinations containing butalbital should not be used in treatment of chronic pain and are not appropriate for long term routine

Narcotics Monitoring System (NMS) Update

Drug Utilization Review & Cost Reduction Strategies. Esther Liu, PharmD, MSIA, CGP Clinical Pharmacist Outcome Resources

A Bill Regular Session, 2015 SENATE BILL 717

Prescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.

NC General Statutes - Chapter 90 Article 5E 1

Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)

Idaho DUR Board Meeting Minutes

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

using analytics to identify and strategically manage patient opioid abuse

Prescription Drug Abuse Task Force Rx Report Card

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

PDMP Tools to Identify Red Flag Situations

Background. CMS finalized new policies for Medicare drug plans to follow starting on January 1,2019.

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Idaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D.

Medicare Part D Overutilization Monitoring System

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

The Wisconsin Prescription Drug Monitoring Program

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Oregon s PDMP: An epidemiological assist tool

Scott Kirby, M.D, Medical Director, North Carolina Medical Board. Chris Ringwalt, Dr.P.H., Senior Scientist, UNC Injury Prevention Research Center

Pennsylvania Prescription Drug Monitoring Program Trends,

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

10 BEFORE THE MEDICAL BOARD OF CALIFORNIA Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official

Aligning Market Objectives and Policy for National Public Health

PRESCRIBING GUIDELINES

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Stark County Safety Council Presentation: Opioid & Anti-Anxiety Medication Use Among Ohio s Injured Workers

Using CURES to combat prescription drug abuse/misuse

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Diabetes Quality Improvement Initiative

Evaluation of the N.C. Prescription

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Follow-up to Previous Reviews

Managing Opioid Overutilization Challenges

Ontario s Narcotics Strategy

See Important Reminder at the end of this policy for important regulatory and legal information.

Overview of ASHP Opioid Efforts

Prescription Monitoring Program (PMP)

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Physician Dispensing: Latest Research From WCRI. November 17, 2017

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

See Important Reminder at the end of this policy for important regulatory and legal information.

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

High-Decile Prescribers: All Gain, No Pain?

Top 10 narcotic pain pills

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Transcription:

Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance (DMA) 1

Controlled Substances The Controlled Substances Act places certain substances into one of five schedules: I-VI Placement is based upon the substance's medical use, potential for abuse, and safety or dependence liability Schedules II-V V include controlled substances with medically accepted uses Most commonly used controlled substances are the opioids and benzodiazepines 2

Controlled Substances Utilization State Fiscal Year 2010 Medicaid Utilization Opioids (Pain Medications) 273,000 recipients $48,336,000 paid claims Examples: Oxycontin, Dilaudid Benzodiazepines (Anxiety Medications) 170,000 recipients $16,251,000 paid claims Examples: Valium, Xanax 3

GAO 2009 Report Controlled Substances Fraud and Abuse Analyzed Medicaid data of five states: California, Illinois, New York, North Carolina, Texas Purpose: To identify fraud and abuse of controlled substances Findings: Doctor shopping and overprescribing of controlled substances Looked at 25 cases: 2 cases from North Carolina involved doctor shopping Recommendations included: Implementing a restricted recipient program Drug Utilization Review (DUR) activities and prior authorizations targeting controlled substances es 4

GAO 2009 Report - Medicaid Response Prior authorization and quantity limits for certain controlled substances Controlled Substance Task Force Recipient Management Lock-In Program Enhanced Drug Utilization Review (DUR) Activities CCNC Pharmacy Home 5

Controlled Substances PA Programs and Quantity Limits Schedule II Narcotics Long-Acting and Short-Acting Schedule II Drugs Quantity Limit based on daily morphine equivalents Prescribers required to read North Carolina Medical Board statement on use of controlled substances for the treatment of pain Sedative Hypnotics Monthly quantity limit of 15 tablets Addresses safety issues with drug class Requires recipient education on good sleep hygiene 6

Controlled Substances PA Programs and Quantity Limits Suboxone and Subutex Abuse of this medication is increasing Limited to opioid dependence indication Daily dose limit of 24mg/day Requires a treatment plan with renewal Prescribers must be registered with the DEA to prescribe 7

Controlled Substances Task Force DMA held first meeting in May 2009 Organized due to increased narcotic utilization among Medicaid recipients Goal: Decrease diversion, misuse and abuse of narcotics Collaboration of agencies throughout state Provides input on initiatives related to controlled substances (i.e., recipient lock-in program) 8

Controlled Substances Task Force Representation includes: Physicians and Pharmacists Pain specialists and substance abuse specialists DMA: Clinical Policy, Program Integrity Other DHHS agencies (Public Health, MH/DD/SAS) CCNC NC Board of Pharmacy Governor s s Institute on Alcohol and Substance Abuse Poison Control Center SBI 9

Special Provision Narcotic Lock-In Program Session Law 2010-31, Section 10.34 Combined efforts by the General Assembly and DHHS Enhances efforts to control narcotic overutilization under Medicaid Requires DMA to lock Medicaid enrollees into a single pharmacy and prescriber when criteria are met Criteria must be approved by NC Physicians Advisory Group 10

Recipient Management Lock-In Program Limits Medicaid recipients to a single pharmacy and a single prescriber Criteria approved by NC Physicians Advisory Group and supported by Controlled Substances Task Force Recipients are identified for the program by meeting the following criteria: Have filled more than 6 prescriptions for either opioid pain relievers or anti-anxiety anxiety (benzodiazepine) medications within a two month period; OR Have been prescribed these medications by more than 3 prescribers within a two month period; OR Have been referred by a provider, DMA or CCNC 11

Recipient Management Lock-In Program About 3,000 Medicaid recipients have been identified 0.2% of 1.6 million current recipients Letters explaining the program were mailed to eligible recipients First recipients were locked-in on October 11 An allowance for emergencies are included in the criteria Program Integrity will conduct audits to ensure compliance Educate on the use of the Controlled Substance Reporting System prior to writing and filling prescriptions 12

Recipient Management Lock-In Program Supports continuity of care Prevents overuse of opioids and benzodiazepines Anticipate cost savings by preventing overutilization and hospitalizations Goal: $2 million annual savings Example: South Carolina Medicaid 40% fewer prescriptions filled 21% reduction in hospital visit 13

Drug Utilization Review (DUR) Federally mandated program under OBRA 1990 Requires prospective and retrospective review of Medicaid pharmacy claims Prospective overutilization and therapeutic duplication alerts Targeted interventions for prescribers and recipients based on retrospective claims data DUR Board: 5 physicians 5 pharmacists 2 members at large 14

Drug Utilization Review (DUR) Increase interventions targeting drugs with high abuse potential Examples of interventions: Lettering prescribers who prescribe over the maximum FDA approved daily dose of benzodiazepines to their patients Additional prescriber interventions for overutilization: Opioid analgesics (Oxycontin, Dilaudid, Morphine) Tramadol (Ultram, Ultram ER) Muscle relaxants (Soma, Skelaxin) 15

CCNC Pharmacy Home Provide education on the Controlled Substances Reporting System Take referrals from prescribers for Medicaid recipients suspected of drug abuse or diversion Make referrals to DHHS and Program Integrity Engage in Network Clinical Director peer visits to practices suspected of being opioid prescribing challenged Support the Medicaid recipient management lock-in program 16

Recommendations Support identification to pick up prescriptions for controlled substances Include method of payment in the Controlled Substance Reporting System Florida-pain clinics and link to controlled substance use in North Carolina needs to be investigated 17